Hydroxychloroquine had no benefit for hospitalized Covid-19 patients, possibly closing door to use of drug
A major clinical trial showed the malaria drug hydroxychloroquine had no benefit for patients hospitalized with Covid-19, likely closing the door to the use of the widely publicized medicine in the sickest patients — a use for which it was widely prescribed as the pandemic hit the U.S.
The results come from a study called RECOVERY, funded by the U.K. government, that sought to randomly assign large numbers of patients to multiple potential treatments in the country’s National Health Service. The goal was to rapidly get answers as to what worked and what didn’t.
